Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
about
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysisEfficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseReal world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.Hepatitis C: efficacy and safety in real life.Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis
P2860
Q33582596-F388D3F0-FE37-4B8B-B5C7-CEB9694AFD0AQ36240269-E384314A-1339-4021-B747-411AFDCEEC0DQ38620762-DA34391C-56F2-4C56-AFF8-C37BDB2F6B63Q38859560-AE295760-1D68-48A1-9E46-DC5567D5A3B9Q38875903-09D849EA-EF3F-4169-A5B7-E60399EC549EQ39040719-72728301-F028-42B9-BE6B-2AC106118B89Q40053677-42D54603-0466-4F0B-A130-5D7D492EB637Q40072613-378561D8-64DA-4ADB-9426-622D8FAB6317Q40141719-ACE0F077-6056-4A2F-B241-A5E9EB0B029FQ40285894-A3E2CFF4-7764-4A5D-A445-88D9591CCD91Q41923104-E2532585-147C-4720-9FE1-7CBFAE106737Q47274792-EF9DD82A-50D8-434A-A575-5DE089B809DBQ47547115-FD6989D9-26A6-499A-9833-7DA9C1ECD4EAQ47564403-C4EFCE2A-BDC0-470B-82F6-75E0B2EFE3B8Q50067496-51E017A2-5BED-4EE5-B317-791192AA90E8Q58714957-303F8CB1-0BB1-47B1-9624-CE57E48768A5
P2860
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Real-world effectiveness and s ...... n in hepatitis C: AMBER study.
@en
Real-world effectiveness and s ...... n in hepatitis C: AMBER study.
@nl
type
label
Real-world effectiveness and s ...... n in hepatitis C: AMBER study.
@en
Real-world effectiveness and s ...... n in hepatitis C: AMBER study.
@nl
prefLabel
Real-world effectiveness and s ...... n in hepatitis C: AMBER study.
@en
Real-world effectiveness and s ...... n in hepatitis C: AMBER study.
@nl
P2093
P50
P356
P1476
Real-world effectiveness and s ...... in in hepatitis C: AMBER study
@en
P2093
A Garlicki
A Piekarska
B Bolewska
D Zarębska-Michaluk
E Karpińska
P304
P356
10.1111/APT.13790
P407
P50
P577
2016-09-09T00:00:00Z